Patient Leaflet Updated 06-Nov-2024 | Astellas Pharma Ltd
Padcev 20 mg and 30 mg powder for concentrate for solution for infusion
Padcev 20 mg powder for concentrate for solution for infusion
Padcev 30 mg powder for concentrate for solution for infusion
enfortumab vedotin
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Padcev is and what it is used for
2. What you need to know before you are given Padcev
3. How to use Padcev
4. Possible side effects
5. How to store Padcev
6. Contents of the pack and other information
Padcev contains the active substance enfortumab vedotin which is made up of a monoclonal antibody linked to a substance intended to kill cancer cells. The monoclonal antibody recognises certain cancer cells and delivers the substance to the cancer cells.
This medicine is used in adults to treat a kind of cancer called bladder cancer (urothelial carcinoma).
People get Padcev when their cancer has spread or cannot be taken out by surgery.
Padcev is given to people that have received an immunotherapy medicine and also received a chemotherapy-containing platinum medicine.
Talk to your doctor immediately if you:
This medicine should not be used in children and adolescents below 18 years of age.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Tell your doctor if you take medicines for fungal infections (e.g., ketoconazole) as they can increase the amount of Padcev in your blood. If you normally take these medicines, your doctor might change it and prescribe a different medicine for you during your treatment.
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before starting this medicine.
You should not use this medicine if you are pregnant. Padcev may harm your unborn baby.
If you are a woman starting this medicine who is able to become pregnant, you should use effective contraception during treatment and for at least 12 months after stopping Padcev.
It is not known if this medicine passes into your breast milk and could harm your baby. Do not breast-feed during treatment and for at least 6 months after stopping Padcev.
Men being treated with this medicine are advised to have sperm samples frozen and stored before treatment. Men are advised not to father a child during treatment with this medicine and for up to 9 months following the last dose of this medicine.
Do not drive or operate machines if you feel unwell during treatment.
You will receive Padcev in a hospital or clinic, under the supervision of a doctor experienced in giving such treatments.
The recommended dose of this medicine is 1.25 mg/kg on days 1, 8 and 15 every 28 days. Your doctor will decide how many treatments you need.
You will receive Padcev by intravenous infusion into your vein over 30 minutes. Padcev will be added to an infusion bag containing either glucose, sodium chloride or Lactated Ringer’s solution before use.
It is very important for you to keep all of your appointments to receive Padcev. If you miss an appointment, ask your doctor when to schedule your next dose.
Do not stop treatment with Padcev unless you have discussed this with your doctor. Stopping your treatment may stop the effect of the medicine.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common (may affect more than 1 in 10 people):
Common (may affect more than 1 in 100 people):
Uncommon (may affect more than 1 in 1000 people):
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP.
The expiry date refers to the last day of that month.
Store in a refrigerator (2ºC to 8ºC). Do not freeze.
Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.
The other ingredients are histidine, histidine hydrochloride monohydrate, trehalose dihydrate and polysorbate 20.
Padcev powder for concentrate for solution for infusion is a white to off-white lyophilized powder.
Padcev is supplied in a box containing 1 glass vial.
This leaflet was last revised in 04/2022.
300 Dashwood Lang Road, Bourne Business Park, Addlestone, KT15 2NX, UK
0800 783 5018
+44 (0) 203 379 8721